Abstract
Background: Few sources regularly monitor hospitalizations associated with respiratory viruses. This study provides current hospitalization trends associated with six common respiratory viruses: COVID-19, influenza, human metapneumovirus (HMPV), parainfluenza virus, respiratory syncytial virus (RSV), and rhinovirus. <br> Objective: This study aims to supplement the surveillance data provided by the CDC by describing latest trends (through October 13, 2024) overall and for each respiratory virus. This study also provides valuable insight into two at-risk populations: infants and children (age 0-4) and older adults (age 65 and over). <br> Methods: Using a subset of real-world electronic health record (EHR) data from Truveta, a growing collective of health systems that provides more than 18% of all daily clinical care in the US, we identified people who were hospitalized between October 01, 2019 and October 13, 2024. We identified people who tested positive for any of the six respiratory viruses within 14 days of the hospitalization. We report weekly trends in the rate of hospitalizations associated with each virus per all hospitalizations for the overall population and the two high-risk sub populations: infants and children and older adults. <br> Results: We included 748,659 hospitalizations of 692,435 unique patients who tested positive for a respiratory virus between October 01, 2019 and October 13, 2024. Overall, the rate of hospitalizations associated with respiratory viruses decreased throughout September 2024; there was a 27.9% reduction in the rate of hospitalizations from the first week of September to the first week of October. COVID-associated hospitalizations saw a notable decline of 46.1%, while influenza-associated hospitalizations remained stable. In contrast, there were increases in hospitalizations for parainfluenza virus (+132.6%), RSV (+149.9%), and rhinovirus (+22.8%). In the first week of October 2024, respiratory virus-associated hospitalizations accounted for 2.0% of all hospitalizations. Overall, test positivity rates also decreased, with an overall drop of 39.3%, particularly in COVID positivity (-53.7%). However, rhinovirus test positivity increased slightly to 21.0%, reflecting a 4.5% rise. <br> Discussion: The data indicates a continued decline in respiratory virus-associated hospitalizations across the overall population, particularly for COVID-19. The notable increases in parainfluenza and RSV hospitalizations suggest a shift in the respiratory virus landscape, highlighting the need for ongoing surveillance. The decrease in test positivity rates for COVID-19 is encouraging, but the rising trend in rhinovirus positivity warrants attention as it may indicate a growing prevalence of this virus.
Competing Interest Statement
All authors are employees of Truveta, Inc
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Normalized electronic health record data are de-identified by expert determination under the HIPAA Privacy Rule before being made available to researchers. In accordance with 45 C.F.R. Para. 46.101 Protection of Human Subjects, our study did not require Institutional Review Board approval because it used only deidentified medical records. All data used in this study are publicly available to Truveta subscribers and may be accessed at studio.truveta.com
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The data has been updated with data from September 2024.
Data Availability
The data used in this study are available to all Truveta subscribers and may be accessed at studio.truveta.com.
